447 related articles for article (PubMed ID: 26467654)
1. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
[TBL] [Abstract][Full Text] [Related]
2. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
Broyles R; Rodden L; Riley P; Berger M
Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion.
Kato H; Hayashi M; Ohashi W; Yamaguchi T; Tanaka S; Kozono A; Gao S; Katai A; Niwa R; Matsuo T; Ishiyama K; Ando T; Ogawa M; Nakayama T
Front Immunol; 2021; 12():740517. PubMed ID: 34603326
[TBL] [Abstract][Full Text] [Related]
4. Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease.
Waheed W; Ayer GA; Jadoo CL; Badger GJ; Aboukhatwa M; Brannagan TH; Tandan R
Muscle Nerve; 2019 Nov; 60(5):528-537. PubMed ID: 31443119
[TBL] [Abstract][Full Text] [Related]
5. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: a case-control study.
Moulis G; Sailler L; Sommet A; Lapeyre-Mestre M; Montastruc JL;
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):314-9. PubMed ID: 21953992
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin use for neurologic diseases.
Koski CL; Patterson JV
J Infus Nurs; 2006; 29(3 Suppl):S21-8. PubMed ID: 16878852
[TBL] [Abstract][Full Text] [Related]
7. Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review.
Abbas A; Rajabally YA
Curr Drug Saf; 2019; 14(1):3-13. PubMed ID: 30332974
[TBL] [Abstract][Full Text] [Related]
8. Significant dermatological side effects of intravenous immunoglobulin.
Hurelbrink CB; Spies JM; Yiannikas C
J Clin Neurosci; 2013 Aug; 20(8):1114-6. PubMed ID: 23659929
[TBL] [Abstract][Full Text] [Related]
9. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.
Nadeau JO; Bhibhatbhan A; McDougall D; Toth C
Clin Neurol Neurosurg; 2010 Jul; 112(6):467-9. PubMed ID: 20227821
[TBL] [Abstract][Full Text] [Related]
10. Not all intravenous immunoglobulin preparations are equally well tolerated.
Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
[TBL] [Abstract][Full Text] [Related]
11. [The use of intravenous immunglobulin in the treatment of autoimmune neuromuscular diseases].
Molnár MJ
Ideggyogy Sz; 2006 Mar; 59(3-4):98-106. PubMed ID: 16634454
[TBL] [Abstract][Full Text] [Related]
12. High-dose intravenous immunoglobulin therapy in dysimmune neuropathies.
Nobile-Orazio E; Bersano A
Neurol Sci; 2002 Apr; 23 Suppl 1():S25-32. PubMed ID: 12032584
[No Abstract] [Full Text] [Related]
13. Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin.
Markvardsen LH; Christiansen I; Andersen H; Jakobsen J
Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):409-12. PubMed ID: 26096187
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune-mediated neuropathies.
Gallia F; Balducci C; Nobile-Orazio E
J Peripher Nerv Syst; 2016 Jun; 21(2):82-4. PubMed ID: 26817673
[TBL] [Abstract][Full Text] [Related]
15. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
[TBL] [Abstract][Full Text] [Related]
16. [Intravenous immunoglobulin-induced eczematous eruption in autoimmune neuromuscular diseases].
Hatake S; Shimizu F; Honda M; Takahashi S; Koga M; Kimura K; Kanda T
Rinsho Shinkeigaku; 2022 Apr; 62(4):267-271. PubMed ID: 35354723
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
[TBL] [Abstract][Full Text] [Related]
18. Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions.
Zubair AS; Rethana M; Ma A; McAlpine LS; Abulaban A; Munro BS; Patwa HS; Nowak RJ; Roy B
J Clin Neuromuscul Dis; 2023 Sep; 25(1):11-17. PubMed ID: 37611265
[TBL] [Abstract][Full Text] [Related]
19. Home IVIG for CIDP: a focus on patient centred care.
Katzberg HD; Rasutis V; Bril V
Can J Neurol Sci; 2013 May; 40(3):384-8. PubMed ID: 23603176
[TBL] [Abstract][Full Text] [Related]
20. Therapy with intravenous immunoglobulins: complications and side-effects.
Wittstock M; Benecke R; Zettl UK
Eur Neurol; 2003; 50(3):172-5. PubMed ID: 14530624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
